Cardiovascular disease and diabetes

HPP worked with the Global Heart Hub to develop a patient-led call to action to improve cardio-diabetes care.


The risk of developing cardiovascular disease is twice as high for people with diabetes as for the general population. But people living with diabetes are often unaware of this, and their risk factors may be poorly managed.

Together, cardiovascular disease (CVD) and diabetes affect hundreds of millions of people across the world. The burden of these diseases is predicted to grow in the coming years, causing millions of avoidable deaths.

People living with type 2 diabetes are at an increased risk of life-changing cardiovascular events such as a stroke, heart attack or CVD-related death. Treating CVD has a major impact on healthcare costs for type 2 diabetes.

In 2022, the Global Heart Hub convened a Cardio-Diabetes Think Tank to fill the gap for a patient -led call to action reflecting the priorities most important to people living with cardio-diabetes. The think tank includes leading experts in diabetes and CVD, such as the World Heart Federation and the International Diabetes Federation, along with representatives of patient advocacy groups and professional societies from across the world.

What we’ve achieved

The Global Heart Hub commissioned HPP to help synthesise the discussions from a round table of the Cardio-Diabetes Think Tank. We drafted a report that unified the voice of the CVD and diabetes communities, developing a call to action and establishing four clear priority actions needed to improve cardio-diabetes care.

Following publication of the report, we brought the call to action to a wider audience with the development of an editorial published in the journal Global Heart.

Key partners and stakeholders

Participants at the GHH Cardio-Diabetes Think Tank:

  • Carlos Castro, patient, CEO Pacientes de Corazón, Mexico
  • Jean-Luc Eiselé, CEO, World Heart Federation
  • Emma Elvin, Senior Clinical Advisor, Diabetes UK, UK
  • Richard Hobbs, Chair, European Primary Care Cardiovascular Society; President, International Primary Care Cardiovascular Society; Professor of Primary Care, University of Oxford; Head of Nuffield Department of Primary Care Health Sciences
  • Neil Johnson, Executive Director, Global Heart Hub; CEO Croi, the Heart & Stroke Charity and National Institute for Prevention and Cardiovascular Health, Ireland
  • Cindy Lamendola, Board Member, Preventive Cardiovascular Nurses Association; Nurse Practitioner/Clinical Research Nurse Coordinator, Stanford University School of Medicine
  • Inese Maurina, patient, CEO,, Latvia
  • Anna Norton, patient, CEO, Diabetes Sisters, USA
  • Jorge Plutzky, Board Member, Worldwide Cardiodiabetes; Director, Preventive Cardiology, Brigham and Women’s Hospital; Principal Investigator and Associate Professor, Harvard Medical School
  • Naveed Sattar, Board Member, Worldwide Cardiodiabetes; Professor of Metabolic Medicine, University of Glasgow; Honorary Consultant in Metabolic Medicine, Glasgow Royal Infirmary
  • Beatriz Yáñez Jiménez, Advocacy Lead, International Diabetes Federation

Contributor to the GHH Cardio-Diabetes Think Tank:

  • Anne-Marie Felton, President, Federation of European Nurses in Diabetes; Honorary Consultant, Queen Mary’s Hospital, London

Project funding

This report and editorial were commissioned by the Global Heart Hub and drafted by The Health Policy Partnership. The Global Heart Hub is supported by unrestricted grants from Boehringer Ingelheim, Novo Nordisk and Roche Diagnostics.